These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16619108)

  • 81. Current concerns and difficulties in the prevention of cardiovascular diseases.
    Rallidis LS; Anastasiou-Nana MI
    Hellenic J Cardiol; 2011; 52(5):437-41. PubMed ID: 21940291
    [No Abstract]   [Full Text] [Related]  

  • 82. Regarding "What a vascular surgeon should know and do about atherosclerotic risk factors".
    Paraskevas KI
    J Vasc Surg; 2009 Sep; 50(3):706-7; author reply 707. PubMed ID: 19700107
    [No Abstract]   [Full Text] [Related]  

  • 83. Intensive glucose control and cardiovascular outcomes.
    Lipska K; Inzucchi SE; Kosiborod M; Krumholz HM
    Lancet; 2009 Aug; 374(9689):522-3; author reply 524. PubMed ID: 19683633
    [No Abstract]   [Full Text] [Related]  

  • 84. [New guidelines on cardiovascular prevention with drugs. The Medical Products Agency recommends risk assessment before choosing a treatment].
    Claesson K; Kahan T; Nilsson PM
    Lakartidningen; 2014 Jul 2-15; 111(27-28):1170-1. PubMed ID: 25162104
    [No Abstract]   [Full Text] [Related]  

  • 85. What target for guidelines: uniformed or tailored?
    Boissel JP; Cucherat M; Gueyffier F
    Am J Hypertens; 1998 Jul; 11(7):890-3. PubMed ID: 9683057
    [No Abstract]   [Full Text] [Related]  

  • 86. Cardiovascular Diseases-A Focus on Atherosclerosis, Its Prophylaxis, Complications and Recent Advancements in Therapies.
    Bułdak Ł
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563086
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Evaluation of Cardiovascular Risk Prediction for the Guidelines of Cardiovascular Diseases Prevention in Japan.
    Ohira T
    J Atheroscler Thromb; 2016; 23(2):169-70. PubMed ID: 26686743
    [No Abstract]   [Full Text] [Related]  

  • 88. Is it Time for Sex-Specific Guidelines for Cardiovascular Disease?
    DeFilippis EM; Van Spall HGC
    J Am Coll Cardiol; 2021 Jul; 78(2):189-192. PubMed ID: 34238440
    [No Abstract]   [Full Text] [Related]  

  • 89. [SSecondary cardiovascular prevention].
    Ledru F
    Rev Prat; 2018 Apr; 68(4):437-438. PubMed ID: 30869396
    [No Abstract]   [Full Text] [Related]  

  • 90. Chronic kidney disease.
    Teramoto T; Sasaki J; Ishibashi S; Birou S; Daida H; Dohi S; Egusa G; Hiro T; Hirobe K; Iida M; Kihara S; Kinoshita M; Maruyama C; Ohta T; Okamura T; Yamashita S; Yokode M; Yokote K
    J Atheroscler Thromb; 2014; 21(3):173-4. PubMed ID: 24335041
    [No Abstract]   [Full Text] [Related]  

  • 91. The challenge of cardiovascular prevention in the elderly: importance of randomized clinical trials.
    Crea F
    Eur Heart J; 2022 Jun; 43(21):1997-2000. PubMed ID: 35641249
    [No Abstract]   [Full Text] [Related]  

  • 92. Transparency rules lead to large fall in positive trial results, analysis finds.
    Mayor S
    BMJ; 2015 Aug; 351():h4304. PubMed ID: 26261243
    [No Abstract]   [Full Text] [Related]  

  • 93. New developments in the treatment and prevention of vascular disease--part 1.
    Katsiki N; Athyros VG; Mikhailidis DP
    Curr Pharm Des; 2010; 16(34):3767-9. PubMed ID: 21128889
    [No Abstract]   [Full Text] [Related]  

  • 94. Re: Does tea affect cardiovascular disease? A meta-analysis.
    Thrift AG; Donnan GA
    Am J Epidemiol; 2002 Sep; 156(5):490; author reply 490-1. PubMed ID: 12196320
    [No Abstract]   [Full Text] [Related]  

  • 95. Personalised cardiovascular disease prevention in the new guidelines.
    Sverre E; Halvorsen S; Løchen ML; Munkhaugen J
    Tidsskr Nor Laegeforen; 2022 Nov; 142(17):. PubMed ID: 36416647
    [No Abstract]   [Full Text] [Related]  

  • 96. Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate 'EUROPA' story.
    Ferrari R; Fox K
    Drugs; 2009; 69(3):265-77. PubMed ID: 19275271
    [TBL] [Abstract][Full Text] [Related]  

  • 97. The current role of ACE-inhibitors for secondary prevention in cardiovascular disease; from pathogenesis to clinical practice.
    Voors AA; van Veldhuisen DJ; van Gilst WH
    Cardiovasc Drugs Ther; 2006 Feb; 20(1):69-73. PubMed ID: 16619108
    [No Abstract]   [Full Text] [Related]  

  • 98. ACE-inhibition for secondary prevention of cardiovascular events--should we change our recommendation after PEACE?
    Ferrari R
    Cardiovasc Drugs Ther; 2006 Feb; 20(1):11-2. PubMed ID: 16649066
    [No Abstract]   [Full Text] [Related]  

  • 99. Drug therapies in the secondary prevention of cardiovascular diseases: Successes, shortcomings and future directions.
    Lonn E; Grewal J
    Curr Vasc Pharmacol; 2006 Jul; 4(3):253-68. PubMed ID: 16842143
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.